Early Diagnosis of Therapy-associated Cardiotoxicity Basing on Multi-tracer Multimodality PET/MRI

Early Diagnosis of Therapy-associated Cardiotoxicity Basing on Multi-tracer Multimodality PET/MRI

Using Multi-tracer to early diagnosis of therapy-associated cardiotoxicity using multimodality PET/MRI.

In this study investigators evaluated cardiac uptake by different molecular probe such as FDG, FAPI-04 using multimodality PET/MRI. Previous studies have shown that increased cardiac uptake of FDG on PET may be an indicator of myocardial injury after chemotherapy. Cardiac magnetic resonance (CMR) allows for multiparametric evaluation of cardiac morphology, ventricular function, myocardial perfusion, and viability. The combination of PET with MR (PET/MR) is therefore an alternative attractive pairing for diagnostic imaging. The aim of this study is to find noninvasive and effective method for early diagnosis of cardiotoxicity after chemotherapy or immunotherapy

Inclusion Criteria:

• availability of a clinical pre- and post-therapy clinical evaluation encompassing electrocardiogram (ECG) ;
• normal findings at pre-therapy clinical evaluation;
• cancer planned chemotherapy or immunotherapy scheme ;
• available staging FDG-PET/CT scan (PET0);

Exclusion Criteria:

• cannot lie supine for half an hour;
• refuse to join the clinical researcher;
• without metal implants.